Verisante completes distribution agreement

Verisante Technology has entered into an agreement with Laserwelt to distribute its Verisante Aura device in Austria, Germany and Liechtenstein.

The Verisante Aura is a device indicated for evaluating skin lesions that may be clinically suspicious for basal cell carcinoma, squamous cell carcinoma or melanoma, according to a news release. Laserwelt distributes dermatologic brands of medical devices for various skincare treatments.

Germany’s incidence rate of skin cancers has tripled since 1980 and is about 20 percent higher than the rest of Europe, according to the news release. The country offers a reimbursement under state health insurance, which covers skin cancer screenings every two years for patients ages 35 and older.